Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||Enzalutamide + ZEN-3694||Preclinical - Cell culture||Actionable||In a preclinical study, ZEN-3694 in combination with Xtandi (enzalutamide) synergistically inhibited proliferation of an AR-positive prostate cancer cell line in culture (Cancer Res 2016;76(14 Suppl):Abstract nr LB-207).||detail...|
|Unknown unknown||prostate cancer||not applicable||Enzalutamide + ZEN-3694||Phase Ib/II||Actionable||In a Phase Ib/II trial, combination of ZEN-3694 and Xtandi (enzalutamide) demonstrated safety in metastatic castration-resistant prostate cancer patients resistant to prior androgen signaling inhibitors, and resulted in a median radiographic progression-free survival (rPFS) of 9.0 months and a composite median radiographic or clinical PFS of 5.5 months, patients with lower baseline AR activity demonstrated prolonged median rPFS (10.4 v 4.3 months) compared to patients with high AR activity (PMID: 32694156).||32694156|
|PubMed Id||Reference Title||Details|
|Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)||Full reference...|
|(32694156)||A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.||Full reference...|